Matt Casey, a founding partner of Ross Feller Casey, told The Philadelphia Inquirer that the FDA's decision to require stronger warning labels on testosterone replacement therapies will be "pivotal" in pending litigation against those drug makers.
"Requiring warning label changes that specifically reference increased risks of heart attacks and strokes will be pivotal in the already existing testosterone litigation nationwide," Casey told the paper, which noted that Ross Feller Casey has 230 testosterone clients, including some who are part of mass tort litigation consolidated before a federal court in Illinois.
Read the story here.
Ross Feller Casey is the nation's recognized leader in lawsuits against the makers of Low T drugs, and was the first to file testosterone-related cases in Philadelphia.
To learn more, go to www.rossfellercasey.com/practice-areas/lowtlawsuit/